Skip to main content

Table 1 Patients Demographic Data

From: Efficacy and safety of Levamisole treatment in clinical presentations of non-hospitalized patients with COVID-19: a double-blind, randomized, controlled trial

Characteristics Placebo/Routine Care Levamisole/ Routine Care
Sex, No. (%)
 Male 13 (52.0) 17 (68.0%)
 Female 12 (48.0) 8 (32.0%)
Age, median (IQR), y
  32.0 (15) 30.0 (14)
Weight, median (IQR), kg
  70.0 (18) 74.0 (18)
Marital status, No. (%)
 Single 6 (24.0) 6 (24.0)
 Married 19 (76.0) 19 (76.0)
Smoking, No. (%)
 Yes 2 (8.0) 4 (16.0)
 No 23 (92.0) 21 (84.0)
Mean of room-air O2 Sats, %
  96.50 96.33
Lung CT-Scan involvement, No. (%)
 Positive 22 (88.0) 22 (88.0)
 Negative 0 (0.0) 2 (8.0)
 None 3 (12.0) 1 (4.0)
Lung CT-Scan involvement Score, %
  2.50 2.75
PCR, No. (%)
 Positive 24 (96.0) 22 (88.0)
 Negative 1 (4.0) 3 (12.0)
Coexisting conditions, No. (%)
 Cardiovascular disease 1 (4.0) 0 (0.0)
 Hypertension 2 (8.0) 1 (4.0)
 Diabetes 3 (12.0) 1 (4.0)
 Asthma 0 (0.0) 2 (8.0)
 Hypothyroidism 1 (4.0) 0 (0.0)
  1. No Number, y year, kg kilogram, O2 Sats oxygen saturation, CT-Scan Computed Tomography Scan, CT involvement Score Scoring the severity by the percentages of each of the five lobes that is involved: 1 for < 5%, 2 for 5–25%, 3 for 26–49%, 4 for 50–75%, and > 75% involvement. The total score is the sum of the individual lobar scores [19], PCR polymerase chain reaction